Myelodysplastic syndrome (MDS) refers to a group of bone marrow disorders that interfere with the healthy production of blood cells. Its a type of blood cancer.
Treatments for MDS can range from long-term medication to stem cell transplants. Your options depend on the type of MDS you have and how serious it is. You might also consider your age and overall health when choosing a treatment plan.
Various treatments can slow disease progression, relieve symptoms, and prevent complications. You can also try certain lifestyle changes and natural remedies that may help relieve your symptoms and improve your quality of life.
Your bone marrow produces immature blood cells, also called stem cells. These then develop into one of three types of mature blood cells:
If you have MDS, not all of these stem cells mature. As a result, immature cells can remain in the bone marrow or die. You will have lower levels of mature blood cells in your bloodstream.
A reduced mature blood cell count is a condition known as cytopenia, and its a main characteristic of MDS. A blood test known as a complete blood count (CBC) is one of the first diagnostic tests your doctor will order if they suspect you have MDS.
Removing bone marrow samples through aspiration and biopsy can also help your doctor better understand the nature of your blood marrow disorder. Once your doctor has diagnosed and treated your MDS, these tests can also show how well your bone marrow is responding to treatment.
You will often have a healthcare team if you have this type of disorder, which may include:
The team will develop a treatment plan thats partially based on the type of MDS you have. The World Health Organization (WHO) identifies six main types of MDS.
Your treatment plan may also be based on the prognostic score (outlook for survival) of the disease. MDS is different from most forms of cancer, which are grouped in stages and grades, because its scored on several factors, including:
Before you start MDS treatment, you might also consider your:
Next, well discuss each of the main treatment options for this group of diseases.
Supportive therapy is meant to treat MDS symptoms and prevent complications, rather than treat the underlying disorder itself. Supportive therapy is often used alongside other treatments.
Examples of supportive therapy include:
Lenalidomide is a type of medication called an immunomodulatory agent. Your doctor may suggest this oral medication if you have MDS and a certain genetic change known as an isolated del(5q) chromosome abnormality.
Lenalidomide helps boost red blood cell production in your bone marrow. Its designed to reduce your dependence on blood transfusions.
Experts in a 2017 research review called it an excellent option for MDS patients with low or intermediate disease risk. Potential side effects include:
Antithymocyte globulin is in a large group of drugs known as immunosuppressants that weaken the bodys immune response. Organ transplant recipients usually take them to help prevent rejection of the new organ. You may take antithymocyte globulin to keep your immune system from attacking stem cells in your bone marrow.
Immunosuppressant therapy may be appropriate for you if you have lower-risk MDS and havent had effective results with ESAs and transfusions. You might also try it if you have one or more autoimmune diseases.
One 2018 study found that antithymocyte globulin was effective in about 50 percent of the MDS cases studied.
Certain chemotherapy drugs, known as hypomethylating agents, activate specific genes in your stem cells to help them mature. Two examples of these agents are azacitidine and decitabine. These drugs are used when your doctor determines there is a serious risk for leukemia, which is a serious potential complication of MDS.
Chemotherapy can help improve blood cell counts, sometimes to the point where you no longer need transfusions, and reduce your risk of leukemia. Potential side effects include:
Other chemotherapy drugs may be given with the goal of killing atypical stem cells and allowing more of your healthy cells to mature.
While high-dose chemotherapy drugs can be very effective at sending MDS into remission, the side effects can be severe. You could experience a serious drop in white blood cells, and later, a greater risk of infections developing and progressing quickly.
A stem cell transplant involves removing some of your bone marrow, usually from the pelvic bone, and replacing it with bone marrow that produces healthy blood cells.
The procedure is usually reserved for more serious cases of MDS. Stem cell transplant is the closest treatment option to a cure, but its an invasive and challenging therapy. Because of this, stem cell transplant is limited to people who are considered healthy enough for both the procedure and the recovery process.
Doctors often use chemotherapy drugs with stem cell transplant to treat MDS. Together, they help support the growth of healthy blood cells to replace unhealthy or atypical cells.
While transplants are often very effective at achieving disease remission, particularly in certain patients, the Aplastic Anemia and MDS International Foundation says that a majority of MDS patients will see their condition return over time.
In addition to traditional medications and procedures to treat MDS, complementary or alternative medicine (CAM) may also help provide you with symptom relief. While these therapies may not affect blood cell production, they may help you cope with symptoms such as anxiety and stress that can come with a chronic disease such as MDS.
Consider some of these treatments and remedies after first discussing them with a healthcare professional:
MDS can affect anyone at any age but generally affects adults ages 70 and older. According to the American Cancer Society (ACS), about 10,000 people are diagnosed with MDS in the United States per year.
Disease outcomes vary considerably. Its difficult to predict someones outcome because people respond differently to treatment.
ACS survival statistics range from a median survival of 8.8 years for people with a very low risk score to less than 1 year for MDS patients with a very high risk score.
These survival rates are based on data that includes years before treatments like chemotherapy were available. Its important to remember that researchers are continuing to develop new treatments that may improve disease outcomes.
You may have no symptoms early on or if you have mild MDS. However, for most people with the disease, anemia (low red blood cell counts) and symptoms such as chronic fatigue and shortness of breath are common.
If you have low white blood cell counts, the risk of serious infection may always be present. Low platelet counts can lead to easy bruising and bleeding complications.
MDS is a type of blood cancer in which your bone marrow doesnt produce high enough levels of mature red blood cells, white blood cells, or platelets.
A variety of treatments are available to manage MDS, including blood transfusions, immunosuppressant drugs, chemotherapy, and stem cell transplants. Each treatment comes with its own risks, but your doctor or cancer treatment team will help guide you toward an approach that may work best for you.
Here is the original post:
Myelodysplastic Syndrome Treatment Options - Healthline
- Adult Stem Cells: What They Are and What They Do - February 6th, 2025
- What Are Adult Stem Cells and Are They Right for You? - February 6th, 2025
- Stem Cell Program | Adult Stem Cells - Boston Children's Hospital - February 6th, 2025
- Different Types Of Stem Cells: Embryonic Vs. Adult ... - January 17th, 2025
- Rejuvenation of Aging Adult Stem Cells to Improve their Regenerative Potential - Frontiers - January 13th, 2025
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
Recent Comments